Exelixis, Inc. (NASDAQ:EXEL) Given Average Rating of “Moderate Buy” by Brokerages

Exelixis, Inc. (NASDAQ:EXEL) has earned a consensus recommendation of “Moderate Buy” from the twenty-three research firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and thirteen have issued a buy recommendation on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $44.0556.

A number of analysts recently weighed in on the stock. William Blair reissued an “outperform” rating on shares of Exelixis in a research note on Tuesday, July 29th. Wall Street Zen raised shares of Exelixis from a “hold” rating to a “buy” rating in a research note on Sunday, September 7th. UBS Group set a $38.00 target price on shares of Exelixis and gave the company a “neutral” rating in a research note on Wednesday, July 30th. Jefferies Financial Group set a $50.00 price target on shares of Exelixis and gave the company a “buy” rating in a research report on Tuesday, June 24th. Finally, Guggenheim restated a “buy” rating and issued a $45.00 price target on shares of Exelixis in a research report on Tuesday, July 29th.

Hedge Funds Weigh In On Exelixis

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Osaic Holdings Inc. boosted its position in Exelixis by 151.9% in the second quarter. Osaic Holdings Inc. now owns 68,276 shares of the biotechnology company’s stock valued at $2,890,000 after buying an additional 41,167 shares in the last quarter. American Trust acquired a new position in Exelixis in the second quarter valued at about $215,000. Centaurus Financial Inc. acquired a new position in Exelixis in the second quarter valued at about $274,000. Orion Porfolio Solutions LLC boosted its position in Exelixis by 20.0% in the second quarter. Orion Porfolio Solutions LLC now owns 55,301 shares of the biotechnology company’s stock valued at $2,437,000 after buying an additional 9,224 shares in the last quarter. Finally, Neuberger Berman Group LLC boosted its position in Exelixis by 32.9% in the second quarter. Neuberger Berman Group LLC now owns 31,406 shares of the biotechnology company’s stock valued at $1,384,000 after buying an additional 7,779 shares in the last quarter. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Exelixis Stock Up 3.6%

NASDAQ EXEL opened at $39.07 on Friday. The stock has a market cap of $10.52 billion, a P/E ratio of 18.78, a PEG ratio of 0.78 and a beta of 0.32. The company’s 50-day simple moving average is $40.11 and its 200 day simple moving average is $39.61. Exelixis has a twelve month low of $25.17 and a twelve month high of $49.62.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Monday, July 28th. The biotechnology company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.63 by $0.12. The business had revenue of $568.26 million for the quarter, compared to analysts’ expectations of $574.36 million. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The firm’s revenue for the quarter was down 10.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.84 earnings per share. Exelixis has set its FY 2025 guidance at EPS. Research analysts anticipate that Exelixis will post 2.04 earnings per share for the current year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.